In a report released today, Ritu Baral from Cowen & Co. maintained a Hold rating on Akcea Therapeutics Inc (AKCA). The company’s shares opened today at $29.99.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 27.6% and a 50.5% success rate. Baral covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Global Blood Therapeutics, and Scholar Rock Holding Corp.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Akcea Therapeutics Inc with a $45 average price target.
See today’s analyst top recommended stocks >>
Based on Akcea Therapeutics Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $63.59 million. In comparison, last year the company had a GAAP net loss of $23.36 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Akcea Therapeutics, Inc. is a late-stage pharmaceutical company, which engages in the development and commercializing of drugs fro the treatment of cardio metabolic diseases caused by lipid disorders. Its products include novel drugs under the followng brands: volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx.
